Infection in organ-transplant recipients

New England Journal of Medicine

Volumn 338, Issue 24, 1998, Pages 1741-1751

  Fishman, Jay A ^a,b   Rubin, Robert H ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CLARITHROMYCIN; COTRIMOXAZOLE; CYCLOSPORIN; ERYTHROMYCIN; FLUCONAZOLE; GANCICLOVIR; ITRACONAZOLE; KETOCONAZOLE; MACROLIDE; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TACROLIMUS;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL INFECTION; CYTOMEGALOVIRUS; DRUG INDICATION; EPSTEIN BARR VIRUS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LUNG INFECTION; LYMPHOPROLIFERATIVE DISEASE; MENINGITIS; MICROBIOLOGICAL EXAMINATION; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; VIRUS INFECTION;

ANTI-INFECTIVE AGENTS; CYTOMEGALOVIRUS INFECTIONS; DIAGNOSIS, DIFFERENTIAL; FEVER; HUMANS; IMMUNOSUPPRESSION; INFECTION; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS; TIME FACTORS;

EID: 0032508056     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199806113382407     Document Type: Review

References (81)

1. Rubin RH. Infection in the organ transplant recipient. In: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host. 3rd ed. New York: Plenum Publishing, 1994:629-705.
2. Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis 1995;21:1077-89.
3. Rubin RH. Infectious disease complications of renal transplantation. Kidney Int 1993,44:221-36.
4. Hopkins CC, Weber DJ, Rubin RH. Invasive aspergillus infection: possible non-ward common source within the hospital environment. J Hosp Infect 1989;12:19-25.
5. Peddi VR, Hariharan S, First MR. Disseminated histoplasma in renal allograft recipients. Clin Transplant 1996;10:160-5.
6. Fishman JA. Pneumocystis carinii and parasitic infections in transplantation. Infect Dis Clin North Am 1995;9:1005-44.
7. Hadley S, Karchmer AW. Fungal infections in solid organ transplant recipients. Infect Dis Clin North Am 1995;9:1045-74.
8. Serody JS, Mill MR, Detterbeck FC, Harris DT, Cohen MS. Blastomycosis in transplant recipients: report of a case and review. Clin Infect Dis 1993;16:54-8.
9. Cohen IM, Galgiani JN, Potter D, Ogden DA. Coccidioidomycosis in renal replacement therapy. Arch Intern Med 1982;142:489-94.
10. Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. Infection in the renal transplant patient. Am J Med 1981;70:405-11.
11. Luft BJ, Naot Y, Araujo FG, Stinson EB, Remington JS. Primary and reactivated toxoplasma infection in patients with cardiac transplants: clinical spectrum and problems in diagnosis in a defined population. Ann Intern Med 1983;99:27-31.
12. Lammermeier DE, Sweeney MS, Haupt HE, Radovancevic B, Duncan JM, Frazier OH. Use of potentially infected donor hearts for cardiac transplantation. Ann Thorac Surg 1990;50:222-5.
13. Nelson PW, Delmonico FL, Tolkoff-Rubin NE, et al. Unsuspected donor pseudomonas infection causing arterial disruption after renal transplantation. Transplantation 1984;37:313-4.
14. Johnson RP, Rubin RH. Respiratory disease in kidney and liver transplant recipients. In: Shelhamer J, Pizzo PA, Parrillo JE, Masur H, eds. Respiratory disease in the immunosuppressed host. Philadelphia: J.B. Lippincott, 1991:567-94.
15. Ettinger NA, Trulock EP. Pulmonary considerations in organ transplantation. Am Rev Respir Dis 1991;143:1386-405, 1991;144:213-23, 433-51.
16. Ettinger NA, Trulock EP. Pulmonary considerations in organ transplantation. Am Rev Respir Dis 1991;143:1386-405, 1991;144:213-23, 433-51.
17. Kanj SS, Sharara AI, Clavien PA, Hamilton JD. Cytomegalovirus infection following liver transplantation: review of the literature. Clin Infect Dis 1996;22:537-49.
18. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994;170:644-52.
19. Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995;59:851-9.
20. van den Berg AP, Klompmaker IJ, Haagsma EB, et al. Evidence for an increased rate of bacterial infections in liver transplant patients with cytomegalovirus infection. Clin Transplant 1996;10:224-31.
21. Bronsther O, Manez R, Kusne S, et al. Posttransplant B, non-A non-B, and cytomegalovirus hepatitis increase the risk of developing chronic rejection after liver transplantation. Transplant Proc 1995;27:1206-7.
22. Hornef MW, Bein G, Fricke L, et al. Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation 1995;60:474-80.
23. Fishman JA, Rubin RH, Koziel MJ, Periera BJG. Hepatitis C virus and organ transplantation. Transplantation 1996;62:147-54.
24. Terrault NA, Wright TL, Pereira BJG. Hepatitis C infection in the transplant recipient. Infect Dis Clin North Am 1995;9:943-64.
25. Agarwal SK, Dash SC, Tiwari SC, Mehta SN, Saxena S, Malhotra KK. Clinicopathologic course of hepatitis B infection in surface antigen carriers following living-related renal transplantation. Am J Kidney Dis 1994;24: 78-82.
26. Poterucha JJ, Wiesner RH. Liver transplantation and hepatitis B. Ann Intern Med 1997;126:805-7.
27. Bocchi EA, Bellotti G, Mocelin AO, et al. Heart transplantation for chronic Chagas' heart disease. Ann Thorac Surg 1996;61:1727-33.
28. de Carvalho VB, Sousa EF, Vila JH, et al. Heart transplantation in Chagas' disease: 10 years after the initial experience. Circulation 1996;94: 1815-7.
29. Sharma RK, Jha R, Kumar P, et al. Visceral leishmaniasis in a renal transplant recipient: diagnostic and therapeutic problems. Am J Nephrol 1996;16:358-60.
30. Aguada JM, Herrero JA, Gavalda J, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Transplant 1997;63:1278-86.
31. Lloveras J, Peterson PK, Simmons RL, Najarian JS. Mycobacterial infections in renal transplant recipients: seven cases and a review of the literature. Arch Intern Med 1982;142:888-92.
32. Rubin RH. Preemptive therapy in immunocompromised hosts. N Engl J Med 1991;324:1057-9.
33. Rubin RH, Tolkoff-Rubin NE. Antimicrobial strategies in the care of organ transplant recipients. Antimicrob Agents Chemother 1993;37:619-24.
34. Hibberd PL, Tolkoff-Rubin NE, Conti D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients: a randomized controlled trial. Ann Intern Med 1995;123:18-26.
35. Wreghitt TG, Hakim M, Gray JJ, et al. Toxoplasmosis in heart and heart and lung transplant recipients. J Clin Pathol 1989;42:194-9.
36. Couvreur J, Tournier G, Sardet-Frismand A, Fauroux B. Transplantation cardiaque ou cardio-pulmonaire et toxoplasmose. Presse Med 1992; 21:1569-74.
37. Orr KE, Gould FK, Short G, et al. Outcome of Toxoplasma gondii mismatches in heart transplant recipients over a period of 8 years. J Infect 1994;29:249-53.
38. Lake KD. Drug interactions in transplant patients. In: Emery RW, Miller LW, eds. Handbook of cardiac transplantation. Philadelphia: Hanley & Belfus, 1995:173-200.
39. Venkataramanan R, Habucky K, Burckart GJ, Ptachcinski RJ. Clinical pharmacokinetics in organ transplant patients. Clin Pharmacokinet 1989; 16:134-61.
40. Amacher DE, Schomaker SJ, Retsema JA. Comparison of the effects of the new azalide antibiotic, azithromycin, and erythromycin estolate on rat liver cytochrome P-450. Antimicrob Agents Chemother 1991;36:1186-90.
41. Whiting PH, Simpson JG, Thomson AW. Nephrotoxicity of cyclospor ine in combination with aminoglycoside and cephalosporin antibiotics. Transplant Proc 1983;15:Suppl 1:2702-5.
42. Rubin RH. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 1990;12:Suppl 7:S754-S766.
43. Fietze E, Prosch S, Reinke P, et al. Cytomegalovirus infection in transplant recipients: the role of tumor necrosis factor. Transplantation 1994;58: 675-80.
44. Chou S. Newer methods for diagnosis of cytomegalovirus infection. Rev Infect Dis 1990;12:Suppl 7:S727-S736.
45. Erice A, Holm MA, Gill PC, et al. Cytomegalovirus (CMV) antigenemia assay is more sensitive than shell vial cultures for rapid detection of CMV in polymorphonuclear blood leukocytes. J Clin Microbiol 1992;30: 2822-5.
46. Fox JC, Griffiths PD, Emery VC. Quantification of human cytomegalovirus DNA using the polymerase chain reaction. J Gen Virol 1992;73: 2405-8.
47. Manez R, Kusne S, Rinaldo C, et al. Time to detection of cytomegalovirus (CMV) DNA in blood leukocytes is a predictor for the development of CMV disease in CMV-seronegative recipients of allografts from CMV-seropositive donors following liver transplantation. J Infect Dis 1996;173:1072-6.
48. Niubo J, Perez JL, Martinez-Lacasa JT, et al. Association of quantitative cytomegalovirus antigenemia with symptomatic infection in solid organ transplant patients. Diagn Microbiol Infect Dis 1996;24:19-24.
49. Grossi P, Kusne S, Rinaldo C, et al. Guidance of ganciclovir therapy with pp65 antigenemia in cytomegalovirus-free recipients of livers from seropositive donors. Transplantation 1996;61:1659-60.
50. Grefte A, van der Giessen M, van Son W, The TH. Circulating cytomegalovirus (CMV)-infected endothelial cells in patients with active CMV infection. J Infect Dis 1993;167:270-7.
51. Sinzger C, Plachter B, Stenglein S, Jahn G. Immunohistochemical detection of viral antigens in smooth muscle, stromal, and epithelial cells from acute human cytomegalovirus gastritis. J Infect Dis 1993;167:1427-32.
52. Fujinami RS, Nelson JA, Walker L, Oldstone MB. Sequence homology and immunologic cross-reactivity of human cytomegalovirus with HLA-DR beta chain: a means for graft rejection and immunosuppression. J Virol 1988;62:100-5.
53. Beck S, Barrell BG. Human cytomegalovirus encodes a glycoprotein homologous to MHC class-I antigens. Nature 1988;331:269-72.
54. Humbert M, Delattre RM, Fattal S, et al. In situ production of interleukin-6 within human lung allografts displaying rejection or cytomegalovirus pneumonia. Transplantation 1993;56:623-7.
55. Lebranchu Y, al Najjar A, Kapahi P, et al. The association of increased soluble VCAM-1 levels with CMV disease in human kidney allograft recipients. Transplant Proc 1995;27:960.
56. Touraine F, Malcus C, Pouteil-Noble C, Touraine JL. Soluble interleukin-2 receptor (S IL-2R) in renal and pancreatic transplantation. Eur Cytokin Netw 1991;2:47-50.
57. Baldwin WM, van Es A, Valentijn RM, van Gemert GW, Daha MR, Vanes LA. Increased IgM and IgM immune complex-like material in the circulation of renal transplant recipients with primary cytomegalovirus infections. Clin Exp Immunol 1982;50:515-24.
58. van Son WJ, van der Bij W, Tegzess AM, et al. Complement activation during an active cytomegalovirus infection after renal transplantation: due to circulating immune complexes or alternative pathway activation? Clin Immunol Immunopathol 1989;50:109-21.
59. von Willebrand E, Pettersson E, Ahonen J, Hayry P. CMV infection, class II antigen expression, and human kidney allograft rejection. Transplantation 1986;42:364-7.
60. Gilbert MJ, Riddell SR, Plachter B, Greenberg PD. Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. Nature 1996;383:720-2.
61. Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996;62:926-34.
62. Falagas ME, Snydman DR, Griffith J, Werner BG. Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients: Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1996;23:468-74.
63. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993;16:677-88.
64. Labalette M, Salez F, Pruvot FR, Noel C, Dessaint JP. CD8 lymphocytosis in primary cytomegalovirus (CMV) infection of allograft recipients: expansion of an uncommon CD8+ CD57-subset and its progressive replacement by CD8+ CD57+ T cells. Clin Exp Immunol 1994;95:465-71.
65. Labalette M, Queyrel V, Masy E, Noel C, Pruvot FR, Dessaint JP. Implication of cyclosporine in up-regulation of Bcl-2 expression and maintenance of CD8 lymphocytosis in cytomegalovirus-infected allograft recipients. Transplantation 1995;59:1714-23.
66. van den Berg AP, Meyaard L, Otto SA, et al. Cytomegalovirus infection associated with a decreased proliferative capacity and increased rate of apoptosis and peripheral blood lymphocytes. Transplant Proc 1995;27: 936-8.
67. Simmons RL, Weil R III, Tallent MB, Kjellstrand CM, Najarian JS. Do mild infections trigger the rejection of renal allografts? Transplant Proc 1970;2:419-23.
68. Reinke P, Fietze E, Ode-Hakim S, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994;344: 1737-8.
69. O'Grady JG, Alexander GJ, Sutherland S, et al. Cytomegalovirus infection and donor/recipient HLA antigens: interdependent co-factors in pathogenesis of vanishing bile-duct syndrome after liver transplantation. Lancet 1988;2:302-5.
70. Keenan RJ, Lega ME, Dummer JS, et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation 1991;51:433-8.
71. Grattan MT, Moreno-Cabral CE, Starnes VA, Oyer PE, Stinson EB, Shumway NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 1989;261:3561-6.
72. Richardson WP, Colvin RB, Cheeseman SH, et al. Glomerulopathy associated with cytomegalovirus viremia in renal allografts. N Engl J Med 1981;305:57-63.
73. Lautenschlager I, Nashan B, Schlitt HJ, Ringe B, Wonigeit K, Pichlmayr R. Early intragraft inflammatory events of liver allografts leading to chronic rejection. Transpl Int 1995;8:446-51.
74. Kowdley KV, Fawaz KA, Kaplan MM. Extrahepatic biliary stricture associated with cytomegalovirus in a liver transplant recipient. Transpl Int 1996;9:161-3.
75. Basgoz N, Preiksaitis J. Post-transplant lymphoproliferative disorder. Infect Dis Clin North Am 1995;9:901-23.
76. Ho M, Miller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis 1985;152: 876-86.
77. Snydman DR, Werner BG, Dougherty NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1993;119:984-91.
78. Falagas ME, Snydman DR, Ruthazer R, Griffith J, Werner BG. Primary cytomegalovirus infection in liver transplant recipients: comparison of infections transmitted via donor organs and via transfusions: Boston Center for Liver Transplantation CMVIG Study Group. Clin Infect Dis 1996;23:292-7.
79. Manion DJ, Vibhagool A, Chou T-C, Kaplan J, Caliendo A, Hirsch M. Susceptibility of human cytomegalovirus to two-drug combinations in vitro. Antiviral Ther 1996;1:237-45.
80. Rubin RH, Green R. Clinical approach to the compromised host with fever and pulmonary infiltrates. In: Rubin RH, Young LS, eds. Clinical approach to infection in the compromised host. 3rd ed. New York: Plenum Publishing, 1994:121-62.
81. Hooper DC, Pruitt AA, Rubin RH. Central nervous system infections in the chronically immunosuppressed. Medicine (Baltimore) 1982;61:166-88.